Intravenous Infusion: From Preclinical Challenge to Clinical Reality

Stéphane Milano, Chief Scientific Officer, WIL Research – Europe

Stéphane Milano, Chief Scientific Officer, WIL Research – Europe
Stéphane Milano is the CSO at WIL Research Europe –Lyon, France where he has worked since 2003. In this role, he provides strategic scientific leadership for European operations as appropriate to the Executive Management Team. As part of his responsibilities, Stéphane is in charge of WIL Research’s Safety Pharmacology and Discovery Services in Europe.

Previously, Stéphane worked as Research Associate for Jouveinal Laboratories, Parke Davis and Pfizer in GI and A&R therapeutic areas. He holds a Ph.D. in Pharmacology, from the University of Marseilles, France where he researched the neurophysiology and pharmacology of the autonomic functions. He has authored more 40 scientific papers and abstracts. Stéphane has also filed two patents on the use of recombinant gastric lipase for treating functional dyspepsia and Modified PAR receptors for selecting compounds. He is an active member of the Safety Pharmacology Society since 2003.

Edward Marsden, Associate Director, WIL Research – Europe
Edward Marsden is an Associate Director and Head of Reproductive and Developmental Toxicology at WIL Research Europe – Lyon, France, where he has worked since 1994. He is responsible for both the scientific and technical staff, specialising in DART and juvenile toxicology studies and for planning future methods and developments in these fields. Previously, Edward worked in the UK for five years where he trained as a reproductive toxicologist with another major contract research organisation. He is a EUROTOX Registered Toxicologist, a council member of the European Teratology Society and member of the British and French Toxicology Societies. In addition to preparing numerous posters for presentation at scientific meetings, Edward is author/co-author of a number of publications and chapters from books including “The Minipig in Biomedical Research” and “Teratogenicity Testing, Methods and Protocols”.

Tim Vanderveen, Vice President, Center for Safety and Clinical Excellence
Tim Vanderveen is Vice President of the Center for Safety and Clinical Excellence. He is responsible for ensuring CareFusion’s commitment to education and innovation. Prior to this, he was the Director of Clinical Affairs, Medication Management Systems, for ALARIS Medical Systems. In addition, he was on the faculty of the College of Pharmacy at Medical University of South Carolina and was Director of the Division of Clinical Pharmacy. He also had a faculty appointment in the College of Medicine and was on staff at the Charleston VA Hospital.

Tim’s clinical practice was in nutritional support, and he co–founded one of the first multi–disciplinary nutrition support teams. During his academic tenure, his research, speaking and publication interests were closely tied to drug therapy in patients receiving parenteral and enteral nutrition. He received his BS and MS degrees from Purdue University School of Pharmacy and his PharmD degree from the Medical University of South Carolina.

Edward Marsden, Associate Director, WIL Research – Europe

Edward Marsden is an Associate Director and Head of Reproductive and Developmental Toxicology at WIL Research Europe – Lyon, France, where he has worked since 1994. He is responsible for both the scientific and technical staff, specialising in DART and juvenile toxicology studies and for planning future methods and developments in these fields. Previously, Edward worked in the UK for five years where he trained as a reproductive toxicologist with another major contract research organisation. He is a EUROTOX Registered Toxicologist, a council member of the European Teratology Society and member of the British and French Toxicology Societies. In addition to preparing numerous posters for presentation at scientific meetings, Edward is author/co-author of a number of publications and chapters from books including “The Minipig in Biomedical Research” and “Teratogenicity Testing, Methods and Protocols”.

Tim Vanderveen, Vice President, Center for Safety and Clinical Excellence

Tim Vanderveen is Vice President of the Center for Safety and Clinical Excellence. He is responsible for ensuring CareFusion’s commitment to education and innovation. Prior to this, he was the Director of Clinical Affairs, Medication Management Systems, for ALARIS Medical Systems. In addition, he was on the faculty of the College of Pharmacy at Medical University of South Carolina and was Director of the Division of Clinical Pharmacy. He also had a faculty appointment in the College of Medicine and was on staff at the Charleston VA Hospital.

Tim’s clinical practice was in nutritional support, and he co–founded one of the first multi–disciplinary nutrition support teams. During his academic tenure, his research, speaking and publication interests were closely tied to drug therapy in patients receiving parenteral and enteral nutrition. He received his BS and MS degrees from Purdue University School of Pharmacy and his PharmD degree from the Medical University of South Carolina.